This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Looking for quick cash? Here are effective ways to access cash quickly, ensuring you meet your financial needs without delay.
25,089 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Coastal thefts show a chilling pattern: suspects watching surfers hide keys, then using stolen info to raid cars and ...
A focused look at how a Medicaid fraud and abuse investigation tied to Rapides Parish can affect family budgets. Lear...
A La Crosse County duo believed they were inches from a life-changing prize. Instead, they were drawn into a months-l...
When a prominent executive questions a public pledge with a personal twist, investors and workers feel the reverberat...
Rent the Runway announces that Jenn Hyman will step down as CEO, with a transition plan that keeps her involved as an...
A doorbell moment can feel like a test of trust. When a delivery driver doesn’t match the app photo, it can raise rea...
Investors are buzzing about SpaceX's ambitious revenue target for 2030 and a bold rival coming from AI. This guide br...
Agility Robotics is pursuing a SPAC merger to go public, a move that would crown it the first pure-play humanoid robo...
Investors have watched Micron stock keep going lower despite upbeat earnings. This deep dive explains the forces behi...
Eli Lilly has powered higher for years, delivering eye-popping gains. But is there more room to run, or is it time to...
Could Nvidia stock really double by 2030? This guide weighs AI-driven growth, competitive risks, and strategies to po...